Ascendis Pharma A/S vs PAGSEG Inc — how do they compare? Ascendis Pharma A/S trades at $256.5 (market cap $16.67B), while PAGSEG Inc trades at $8.7 (market cap $2.48B). The key difference: Ascendis Pharma A/S is far larger — about 6.7× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PAGS | |
|---|---|---|
Market Cap | $16.67B | $2.48B |
Sector | Health | Technology |
52-Week High | $277.18 | $12.00 |
52-Week Low | $189.74 | $8.38 |
Enterprise Value | $17.04B | $10.22B |
Dividend Yield | — | 11.7% |
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.46, showing minimal daily movement (-0.06%). The stock maintains a bullish technical outlook with strong analyst support (92% buy ratings) and a consensus price target of $309.75, representing 21% upside potential. Recent developments include positive clinical trial updates for TransCon CNP in achondroplasia and inclusion in multiple Russell indexes, signaling growing institutional recognition. Revenue growth has been robust, increasing from $51M in 2022 to $720M in 2025, though the company remains unprofitable with a net loss of $228M in 2025.
ASND presents a growth investment opportunity with multiple product catalysts and improving financial trajectory, though significant risks remain. The company's premium valuation (P/E 29.05, P/S 15.68) reflects high growth expectations, while negative shareholder equity and substantial debt require careful monitoring. Positive cash flow generation since 2024 and upcoming regulatory milestones provide potential upside, but execution risks and clinical trial outcomes could impact shareholder value.
PAGS trades at $8.72, down 3.96% today, with mixed technical signals showing bearish moving averages but neutral oscillators. The stock presents compelling value with a P/E of 6.17 and P/B of 0.87, supported by strong profitability metrics including 53.05% gross margin and 14.52% ROE. Recent Q2 2026 earnings beat expectations with EPS of $0.41 versus $0.389 expected, while Q1 2026 showed a slight miss.
Analyst consensus remains bullish with 62.5% buy ratings and a $11.45 price target, suggesting 31% upside potential. Key risks include competitive pressures in Brazil's digital banking sector and macroeconomic sensitivity to interest rate cycles. The company maintains solid cash flow generation with $7.56B operating cash flow in 2025, supporting ongoing business expansion.
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →